Bioqual Net Income/Loss 2010-2025 | BIOQ
Bioqual net income/loss from 2010 to 2025. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
| Bioqual Annual Net Income/Loss (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $1 |
| 2022 | $5 |
| 2021 | $6 |
| 2020 | $4 |
| 2019 | $3 |
| 2018 | $4 |
| 2017 | $0 |
| 2016 | $0 |
| 2015 | $0 |
| 2013 | $0 |
| 2012 | $0 |
| 2011 | $0 |
| 2010 | $0 |
| 2009 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $0.040B | $0.059B |
| BIOQUAL, Inc., formerly Diagnon Corporation, develops, produces and sells diagnostic test kits incorporating monoclonal antibodies to diagnose certain anemias, infections, and parasitic diseases. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quest Diagnostics (DGX) | United States | $19.868B | 19.58 |
| Encompass Health (EHC) | United States | $12.183B | 25.83 |
| DaVita (DVA) | United States | $10.978B | 15.44 |
| Chemed (CHE) | United States | $8.483B | 26.66 |
| Elanco Animal Health (ELAN) | United States | $6.417B | 13.74 |
| Option Care Health (OPCH) | United States | $5.441B | 24.26 |
| RadNet (RDNT) | United States | $4.587B | 291.14 |
| Amedisys (AMED) | United States | $3.105B | 20.89 |
| LifeStance Health (LFST) | United States | $2.271B | 0.00 |
| Addus HomeCare (ADUS) | United States | $2.054B | 22.55 |
| Astrana Health (ASTH) | United States | $1.524B | 37.75 |
| U.S Physical Therapy (USPH) | United States | $1.213B | 31.31 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.169B | 66.56 |
| Pennant (PNTG) | United States | $1.042B | 38.25 |
| Atai Life Sciences (ATAI) | Germany | $0.331B | 0.00 |
| Daxor (DXR) | United States | $0.037B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.024B | 0.00 |
| Ontrak (OTRK) | United States | $0.007B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |